Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag England’s NHS will fund ruxolitinib cream for teens and adults with facial vitiligo, the first approved treatment in the UK.

flag The NHS in England will now fund ruxolitinib cream (Opzelura) for patients aged 12 and over with non-segmental vitiligo affecting the face, marking the first approved treatment for the condition in the UK. flag NICE approved the topical JAK inhibitor after a revised pricing agreement, citing strong clinical benefits and value for money. flag The cream, applied twice daily, helps restore skin pigmentation by targeting the immune system’s attack on melanocytes, with trials showing significantly greater repigmentation than placebo. flag It is recommended for those who haven’t responded to or cannot use first-line treatments. flag The decision, welcomed by patient advocates, could benefit over 80,000 people and addresses a long-standing unmet medical need, particularly for those with darker skin tones and significant psychosocial impacts.

7 Articles